The latest price target for CNS Pharma (NASDAQ:CNSP) was reported by Maxim Group on September 10, 2024. The analyst firm set a price target for $0.50 expecting CNSP to rise to within 12 months (a possible 344.84% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for CNS Pharma (NASDAQ:CNSP) was provided by Maxim Group, and CNS Pharma upgraded their buy rating.

The last upgrade for CNS Pharmaceuticals Inc happened on September 10, 2024 when Maxim Group raised their price target to $0.5. Maxim Group previously had a hold for CNS Pharmaceuticals Inc.

There is no last downgrade for CNS Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CNS Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CNS Pharma was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.

While ratings are subjective and will change, the latest CNS Pharma (CNSP) rating was a upgraded with a price target of $0.00 to $0.50. The current price CNS Pharma (CNSP) is trading at is $0.11, which is within the analyst’s predicted range.